Wuhan Haite Biopharmaceutical Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Public

  • Employees
  • 958

Employees

  • Stock Symbol
  • 300683

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.82
  • (As of Friday Closing)

Wuhan Haite Biopharmaceutical General Information

Description

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Haite Science and Technology Park, Wuhan Economic Development Zone
  • Wuhan, Hubei 430056
  • China
+86 027
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
SHE
Corporate Office
  • Haite Science and Technology Park, Wuhan Economic Development Zone
  • Wuhan, Hubei 430056
  • China
+86 027

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Wuhan Haite Biopharmaceutical Stock Performance

As of 20-Nov-2026, Wuhan Haite Biopharmaceutical’s stock price is $2.82. Its current market cap is $369M with 131M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.82 $2.98 $2.82 - $7.37 $369M 131M 5.92M -$0.21

Wuhan Haite Biopharmaceutical Financials Summary

As of 30-Sep-2026, Wuhan Haite Biopharmaceutical has a trailing 12-month revenue of $62.9M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 449,103 426,283 316,434 515,596
Revenue 62,865 75,292 90,444 85,130
EBITDA (29,979) (20,363) 878 (12,511)
Net Income (27,920) (32,159) (9,665) (17,078)
Total Assets 360,196 368,251 402,273 419,159
Total Debt 5,133 10,143 6,370 9,304
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Wuhan Haite Biopharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Wuhan Haite Biopharmaceutical‘s full profile, request access.

Request a free trial

Wuhan Haite Biopharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Wuhan Haite Biopharmaceutical Investments & Acquisitions (4)

Wuhan Haite Biopharmaceutical’s most recent deal was a Merger/Acquisition with Shadong Biotechnology for . The deal was made on 27-Feb-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Shadong Biotechnology 27-Feb-2024 Merger/Acquisition Biotechnology
Shadong Biotechnology 22-Dec-2021 Secondary Transaction - Private Biotechnology
CVI Pharmaceuticals 21-Jul-2021 Later Stage VC Drug Discovery
Weijia Pharmaceutical 08-Dec-2020 Merger/Acquisition Drug Discovery
To view Wuhan Haite Biopharmaceutical’s complete investments and acquisitions history, request access »

Wuhan Haite Biopharmaceutical ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Wuhan Haite Biopharmaceutical’s complete esg history, request access »

Wuhan Haite Biopharmaceutical Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Weijia Pharmaceutical Xiamen, China 2017
Shadong Biotechnology Beijing, China 2001

Wuhan Haite Biopharmaceutical FAQs

  • When was Wuhan Haite Biopharmaceutical founded?

    Wuhan Haite Biopharmaceutical was founded in 1992.

  • Where is Wuhan Haite Biopharmaceutical headquartered?

    Wuhan Haite Biopharmaceutical is headquartered in Wuhan, China.

  • What is the size of Wuhan Haite Biopharmaceutical?

    Wuhan Haite Biopharmaceutical has 958 total employees.

  • What industry is Wuhan Haite Biopharmaceutical in?

    Wuhan Haite Biopharmaceutical’s primary industry is Drug Discovery.

  • Is Wuhan Haite Biopharmaceutical a private or public company?

    Wuhan Haite Biopharmaceutical is a Public company.

  • What is Wuhan Haite Biopharmaceutical’s stock symbol?

    The ticker symbol for Wuhan Haite Biopharmaceutical is 300683.

  • What is the current stock price of Wuhan Haite Biopharmaceutical?

    As of 20-Nov-2026 the stock price of Wuhan Haite Biopharmaceutical is $2.82.

  • What is the current market cap of Wuhan Haite Biopharmaceutical?

    The current market capitalization of Wuhan Haite Biopharmaceutical is $369M.

  • What is Wuhan Haite Biopharmaceutical’s current revenue?

    The trailing twelve month revenue for Wuhan Haite Biopharmaceutical is $62.9M.

  • What is Wuhan Haite Biopharmaceutical’s annual earnings per share (EPS)?

    Wuhan Haite Biopharmaceutical’s EPS for 12 months was -$0.21.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process